UNS - Unilife Corporation

[bilo83]

This is what UNS holders have been waiting for. Amazing trading on nasdaq last night! Last trade $ 17.90 ($3.31 equivaluent for UNS!!!)

Best Bid / Ask $ 10.22 / $ 18
High / Low $ 26.40 / $ 11
Share Volume 28,890

Better volume, but I get the feeling order book was thin which explains the wild swings. Should be a very good trading day here, but I feel volumes will have to pick up on nasdaq to close the valuation gap.

 

[chb]

up 25 cents as of now(8:39 WST)

nice!

i should have bought more


hopefully more rises to come in the future

 

[UBIQUITOUS]

up 25 cents as of now(8:39 WST)

nice!

i should have bought more


hopefully more rises to come in the future

chb in my opinion this is just the beginning. Next week should be a ripper with the Sanofi Aventis therapeutic drugs list agreement due. At this point we will be able to narrow down the size of Unilife's market. I really to expect it to be $1billion-$2billion in 5-7 years, or $25-$50 USD a share.

 

[chb]

Just read the announcement, seems like it depends if they both agree on a list. Time to wait and see I suppose...


Not sure whether I should put a bit more into it! indecisions

 

[UBIQUITOUS]

Just read the announcement, seems like it depends if they both agree on a list. Time to wait and see I suppose...


Not sure whether I should put a bit more into it! indecisions

I'm sure they will. It would make no sense for both companies to be involved over a period of several years, and then squabble at the last moment. Don't forget that Sanofi Aventis have paid Unilife millions to industrialize their syringes.

 

[chb]

Got smacked again last night in the US. I wonder if someone knows something we don't about the agreement


Have no doubt it'll pick up again in a few weeks

 

[pacestick]

Got smacked again last night in the US. I wonder if someone knows something we don't about the agreement

The downward push on the nasdaq is almost certainly due to more common stock being available .UNiS posted on its website that computershare had been unable to process the transfers due to the severe weather in the USA . However as the law of supply and demand kicks in the sp on the nasdaq has fallen and the sp on the asx has risen although no where near predictions . I suspect that the asx price will move up again on monday, however any major increase in sp is dependent on
1. a unis announcements re sales of unitract
2. finalisation of the exclusive agreement with Sanofi Aventis
3. Announcement of fuirther agreements with other pharmas

AS 3 is dependent on 2 and 2 is due by the end of the month which is 1 week away
I would expect the sp to go upwards in the next two weeks

disclosure I hold uns cdis

 

[LeeTV]

A great close today on good volume VWAP $1.53. Futures are looking good for a green day on the NASDAQ.

Don't forget that CEO Alan Shortall will be ringing the NASDAQ closing bell at around 3.45 pm EST(4.45 am Perth time)today which can be viewed live here.

Unilife is pleased to advise that CEO Alan Shortall will preside over the NASDAQ closing bell ceremony on Monday, February 22, 2010. Members of Unilife's management team and guests will join Mr. Shortall at the ceremony, which will take place at the NASDAQ MarketSite in Times Square and will be broadcast live.

 

[LeeTV]

Unilife Corporation rings the NASDAQ Closing Bell

Unilife Corporation Donates First Shipment of Unitract(TM) Safety Syringes to Haitian Relief Efforts

 

[LeeTV]

This is the link to the full closing ceremony: Unilife Corporation rings the NASDAQ Closing Bell

 

[UBIQUITOUS]

Unilife Corporation rings the NASDAQ Closing Bell

Unilife Corporation Donates First Shipment of Unitract(TM) Safety Syringes to Haitian Relief Efforts

I didn't donate to Haiti, but through Unilife now feel as though I have. They must be confident of future revenue to be giving them away before having sold any.

 

[chb]

Anyone else worried that there has been a steady decline in UNIS? Perhaps there is going to be a negative announcement coming...

 

[LeeTV]

Anyone else worried that there has been a steady decline in UNIS? Perhaps there is going to be a negative announcement coming...

Never like to see the sp declining, obviously, but I think UNIS is just reaching parity with UNS(CDI's).

The after hours finish of UNIS overnight was $8 USD
8.00 USD = 8.95536 AUD / 6(CDI's) = $1.49 AUD
The close for UNS on Wednesday was $1.475 AUD

So we have reached parity, now who is leading who is the question? We really need the announcement out about the exclusivity agreement, which is over due, to put a rocket under the sp.

 

[LeeTV]

Stock Alert for Unilife Corp. (UNIS)
Posted by BeaconEquity.com on Feb 24, 2010

Unilife Corp. (NASDAQ: UNIS) made its debut into the American markets last week. We had a chance to speak with the CEO, Alan Shortall today to figure out what this seemingly unknown company was all about. We left the call having gained some new insight into the Company and the direction it appears to be heading. The management team is absolutely ecstatic with where the Company is going and how it has grown in the past 7 years. There are a few main reasons why this company is so excited about the future; their exclusive contract with Pharmaceutical giant Sanofi-Aventis, their patented range of retractable syringes, and the growing demand for a safer needle alternative.

Unilife is in a $40 million exclusive rights agreement with Sanofi-Aventis. The Pharmaceutical company has exclusive rights to negotiate the purchase of Unilifes patent protected Ready-to-Fill (Prefilled) syringe, the Unifill. The Unifill is the worlds first and only known prefilled syringe with automatic safety features fully integrated within the barrel. This contract has helped Unilife fund the industrial program they started in 2008. In addition, the Company has retained the right to negotiate with other pharmaceutical companies seeking to use the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those retained exclusively by Sanofi-Aventis. With the $1.5 billion market for prefilled syringes growing in double-digits every year, this allows ample room for long-term growth. The Company is now building a state-of-the art facility in Pennsylvania with the capacity to manufacture up to 400 million of its syringes per year.

Unilife is developing a full proprietary range of retractable syringes that are divided into two product brands the Unitract range of plastic syringes for use with vials and the Unifill range of glass syringes that are prefilled by pharmaceutical companies with an injectable drug or vaccine. All Unilife syringes share the same unique technology platform; the syringe is able to retract the needle while it is still in the patient, and secondly, the person administering the injection controls the speed of this needle retraction into the barrel. This is different from the competition which uses syringes with safety features that must either be clipped on, or do not offer controlled needle retraction. The competing syringes in the prefilled syringe market are also bigger, which adds to storage and transportation costs. The Unifill syringe is the most efficient, safe and effective needle on the market. Of course best of all, this technology is patented.

Lastly, the demand for something like safe needles is astronomical. The CEO shared some sobering statistics about injuries and deaths due to needle stick injuries. 1.3 million people die every year due to unsafe needle use. Furthermore, in the United States, where legislation has been passed on safe needle use, more than 600,000 healthcare workers receive a needlestick injury annually. There is without a doubt a need and demand for safe needles, making this both a lucrative and socially beneficial market.

Unilife has the potential to be a big-time player in a much needed industry, because of its contract with Sanofi-Aventis, its patented Unifill syringe and the demand for a safer needle alternative. The CEO was extremely excited and has good reason to be. Keep an eye on UNIS as it is now publicly traded on the NASDAQ.

 

[chb]

Never like to see the sp declining, obviously, but I think UNIS is just reaching parity with UNS(CDI's).

The after hours finish of UNIS overnight was $8 USD
8.00 USD = 8.95536 AUD / 6(CDI's) = $1.49 AUD
The close for UNS on Wednesday was $1.475 AUD

So we have reached parity, now who is leading who is the question? We really need the announcement out about the exclusivity agreement, which is over due, to put a rocket under the sp.

I would imagine it to be UNIS. UNIS had a great start and this resulted in a major jump in UNS. Days after, UNS is following UNIS down.

 

[pacestick]

Basically investors are are sitting around watching traders play with these shares something that would not have happened twelve to eighteen months ago the volume wasnt there. Investors are waiting for an announcement re finalisation of the restriction agreement with Sanofi which is due tomorrow if the last announcement is accurate and i have no reason to believe that it wont be.
This will free UNIS/UNS to follow up initial negotiations with other pharma .The length of time untill we get announcements on agreements with those other companies will probably depend on how far those initial negotiations had proceded.
In the meantime this link gives the average analysts predictions of the rise in
the sp by comparing their estimates to the current price . I have to assume that their is an error either in my calculation or a typo in the report as i come up with about $389.00 a cdi wheras i was expecting a top of about 10% of that any comments
http://www.nasd100.com/2010/02/top-...ghest-upside-potential-as-of-feb-23-2010.html

 

[UBIQUITOUS]

In the meantime this link gives the average analysts predictions of the rise in
the sp by comparing their estimates to the current price . I have to assume that their is an error either in my calculation or a typo in the report as i come up with about $389.00 a cdi wheras i was expecting a top of about 10% of that any comments
http://www.nasd100.com/2010/02/top-...ghest-upside-potential-as-of-feb-23-2010.html

Pace, that 30603.4% potential upside is incorrect, as at the time the sp was about 15c higher. So the potential upside now is more like 34,000%.

Remember, this is potential upside, ie if Unilife's syringes become the industry standard syringe, many years in the future, and if they can stave of a takeover attempt.

 

[Santoro]

Investors are waiting for an announcement re finalisation of the restriction agreement with Sanofi which is due tomorrow if the last announcement is accurate and i have no reason to believe that it wont be.

Where in the announcements or press releases does it mention the "finalisation of the restriction agreement with Sanofi " date being tomorrow?

 

[UBIQUITOUS]

http://www.sec.gov/Archives/edgar/data/1476170/000095012310007104/c94794e10v12bza.htm

Strategic Partnership with sanofi-aventis

We started to collaborate with sanofi-aventis in 2003 for the development of the Unifill syringe as a next-generation drug delivery safety device. Sanofi-aventis is a large, global pharmaceutical company, whose products span multiple therapeutic areas, including cardiovascular diseases, thrombosis, oncology, metabolic diseases, internal medicine and vaccines. We believe that sanofi-aventis is currently the world’s largest purchaser of prefilled syringes.
We have signed an exclusive licensing agreement with sanofi-aventis. Under the exclusive licensing agreement, we have granted sanofi-aventis an exclusive license to certain of our intellectual property in order and solely to develop, in collaboration with us, the Unifill syringe for use in and sale to the prefilled syringe market within those therapeutic areas to be agreed upon between us, and a non-exclusive license outside those therapeutic areas that are exclusive to sanofi-aventis or after the expiration of the exclusive license with sanofi-aventis. Pursuant to the exclusive licensing agreement, sanofi-aventis has paid to us a €10 million upfront one-time fee. The exclusive license granted thereunder has an initial term expiring on June 30, 2014, unless we and sanofi-aventis fail to agree by February 28, 2010 upon the list of therapeutic areas that are exclusive to sanofi-aventis, in which event the exclusive license will have a term until June 29, 2012 for all therapeutic areas. If, during the term of the exclusive license, sanofi-aventis has purchased the Unifill syringe for use with a particular drug product, sanofi-aventis will receive a ten-year extension of the term of the exclusive license, which extension will be reduced to five years if sanofi-aventis does not sell a minimum of 20 million units of the product in any of the first five years of such ten-year extension period.
Under the exclusive licensing agreement, we are not precluded from using certain of our intellectual property to develop, license and sell any products in any market other than the ready-to-fill syringe market, or from entering into licensing or other business arrangements with other pharmaceutical companies for the ready-to-fill syringe market outside those therapeutic areas that are exclusive to sanofi-aventis, or after the expiration of the exclusive license with sanofi-aventis. If we grant a license to a third party in respect of the ready-to-fill syringe market, then we are required to pay sanofi-aventis 70% of any access, license or other upfront fee received from such third party for access to purchase the products until our payments to sanofi-aventis have totaled €10 million, following which we are required to pay 30% of such fees we receive through the end of the initial exclusivity period. We are also required to pay sanofi-aventis an annual royalty payment of 5% of the revenue generated from any sale of the Unifill syringe to third parties, up to a maximum amount of €17 million in such royalty payments.
On June 30, 2009, we signed an industrialization agreement with sanofi-aventis. The industrialization agreement sets forth the terms for the collaboration between the parties to design, develop, scale up and industrialize the Unifill syringe, including the timetable and milestones for the industrialization program. Under the industrialization agreement, sanofi-aventis has agreed to provide up to €17 million in payments to us based on milestones we achieve in our industrialization program. The industrialization program began in July 2008 and is scheduled to be completed by the end of 2010. From October 2008 through December 2009, we have received payments of €11.5 million under the industrialization agreement. Key hurdles which remain until we complete the industrialization program include the development of a pilot automated assembly system, the completion of a new manufacturing facility and the establishment of a designated cleanroom for the installation of the automated assembly system. The industrialization agreement required sanofi-aventis to provide a list to us that specifies therapeutic drug classes for which it seeks to market the Unifill syringe on an exclusive basis. We and sanofi-aventis are discussing the exclusivity list sanofi-aventis provided us and if the list is agreed, sanofi-aventis will retain exclusive rights to the use of the product within these designated therapeutic drug classes until June 30, 2014, subject to the extension described above. If we are unable to reach an agreement on the list, then sanofi-aventis will retain full exclusivity across all therapeutic classes only until June 29, 2012. Unless terminated earlier, the industrialization agreement has a term until the completion of the industrialization program.
The industrialization agreement provides that, subject to the full completion of the industrialization program, the parties will negotiate a supply agreement for the manufacture and purchase of the final product on a commercial scale. The supply agreement will provide that sanofi-aventis and its affiliates will purchase the final product exclusively from us, and the industrialization agreement provides that we are not required to commit more than 30% of our expected installed production capacity to sanofi-aventis and its affiliates for the 12 months following the receipt of a purchase order. Any order of sanofi-aventis, together with its other orders, that will exceed the 30% capacity limit will require up to a maximum of 24 months lead time before we are required to commence delivery of that order.


9

Table of Contents

Pursuant to the industrialization agreement, if UMSL agrees to, or proposes to agree to, a change of control with a third party, UMSL must give a written notice to sanofi-aventis, who will be entitled, within five business days, to make an offer on at least equivalent terms. In the absence of an improved change of control proposal, UMSL must accept the matching offer of sanofi-aventis. If UMSL receives an improved change of control offer from the third party, then UMSL must give a further notice to sanofi-aventis for it to make a further matching offer. In addition, if during the term of the industrialization agreement, a change of control that does not involve sanofi-aventis, or its affiliates, obtaining control of UMSL (i) is not recommended by UMSL’s board of directors, (ii) will cause harm to sanofi-aventis, as defined in the agreement or (iii) under which Mr. Alan Shortall, our CEO and director, is not to continue in such capacities for at least two years after the change of control, then sanofi-aventis will have the right to terminate the industrialization agreement within ten business days after receiving a notice from UMSL, or after it otherwise becomes aware of the change of control. Pursuant to the industrialization agreement, a change of control means, in general terms, a change in the ownership of 50% or more of UMSL’s shares or the power to determine the majority composition of UMSL’s board of directors or any other event that UMSL’s board determines to be a change of control event.

 

[UBIQUITOUS]

One way or another, there should be an announcement tomorrow. The question is whether this needs to be Australia time or US time.

Personally, rather in than out.